- Home
- ROIV vs FIS Comparison
ROIV vs FIS Comparison
Compare ROIV & FIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | FIS |
|---|---|---|
| Founded | 2014 | 1968 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 20.7B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ROIV | FIS |
|---|---|---|
| Price | $34.40 | $40.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $28.94 | ★ $72.23 |
| AVG Volume (30 Days) | ★ 7.1M | 5.4M |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 3.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.03 |
| Revenue | $8,260,000.00 | ★ $10,677,000,000.00 |
| Revenue This Year | N/A | $30.41 |
| Revenue Next Year | $744.61 | $4.76 |
| P/E Ratio | ★ N/A | $8.11 |
| Revenue Growth | N/A | ★ 5.43 |
| 52 Week Low | $12.28 | $37.42 |
| 52 Week High | $37.97 | $70.27 |
Technical Indicators
Market Signals| Indicator | ROIV | FIS |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 44.09 |
| Support Level | $33.01 | $39.68 |
| Resistance Level | $35.70 | $40.61 |
| Average True Range (ATR) | 1.12 | 1.15 |
| MACD | -0.29 | -0.16 |
| Stochastic Oscillator | 20.61 | 10.80 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. In a recent deal with Global Payments, FIS sold off its remaining interest in Worldpay and acquired Global Payment's issuer processing business.